Aurobindo Pharma receives FDA approval for Isosulfan blue injection

Isosulfan blue injection is used in a lymphography procedure

id-100148437

Isosulfan Blue Injection upon subcutaneous administration, delineates the lymphatic vessels

Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Isosulfan Blue Injection, 1 percent (50 mg/5 mL) single-dose vials. The product is expected to be launched in Q4 FY15-16.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) LymphazurinTM Injection, 1 percent, of Covidien. Isosulfan Blue Injection under Cardio Vascular therapeutic group, is used in a lymphography procedure.

Isosulfan Blue Injection upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. The approved product has an estimated market size of $57 million for the twelve months ending December 2015 according to IMS.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X